°ü·ù ½Ã½ºÅÛ ½ÃÀå : ±â¹ýº°, ±¸¼º¿ä¼Òº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº° ¹× ¿¹Ãø(2023-2032³â)
Perfusion Systems Market - By Technique (Hypothermic Machine Perfusion, Normothermic Machine Perfusion), By Component (Oxygenators, Heart-Lung Machine, Perfusion Pumps, Monitoring System), By Application, By End-use & Forecast, 2023 - 2032
»óǰÄÚµå
:
1355823
¸®¼Ä¡»ç
:
Global Market Insights Inc.
¹ßÇàÀÏ
:
2023³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 180 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è °ü·ù ½Ã½ºÅÛ ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö CAGR 4.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÉÇ÷°ü ¹× È£Èí±â ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ Àå±â ÀÌ½Ä ¹× ¼ö¼úÀ» À§ÇÑ °í±Þ °ü·ù ½Ã½ºÅÛÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÇ·á±â¼úÀÇ ¹ßÀüÀº ´õ¿í Á¤±³Çϰí È¿À²ÀûÀÎ °ü·ù ½Ã½ºÅÛÀ» ¸¸µé¾î³»°í ÀÖ½À´Ï´Ù. °ü·ù¸¦ Æ÷ÇÔÇϰųª °ü·ù¿Í °ü·ÃµÈ Ãֽбâ¼ú ±â±â¿¡ ´ëÇÑ FDA ½ÂÀÎÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2023³â 8¿ù, ¼±µµÀû ÀÇ·á ±â¼ú ±â¾÷ÀÎ ¸®¹Ù³ë¹Ù(LivaNova PLC)´Â Essenz(TM) In-Line Blood Monitor(ILBM)ÀÇ FDA ¹× CE ¸¶Å© ±ÔÁ¦ ½ÂÀÎÀ» ȹµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Essenz(TM) °ü·ù ½Ã½ºÅÛ¿¡ ÅëÇÕµÈ ÀÌ ¸ð´ÏÅÍ´Â °ü·ù ±â¼úÀÚ°¡ ½Ã½ºÅÛ Á¶Á¾¼®¿¡¼ Ç÷¾× ¸Å°³º¯¼ö¿¡ Á¢±ÙÇÏ°í Æí¸®ÇÏ°Ô °ü¸®ÇÒ ¼ö ÀÖµµ·Ï ÇØ º°µµÀÇ ¸ð´ÏÅͳª Ȧ´õ°¡ ÇÊ¿ä ¾ø°Ô ÇÕ´Ï´Ù. °í·ÉÈ Àα¸ÀÇ Áõ°¡´Â Àå±â À̽Ŀ¡ ´ëÇÑ ¼ö¿ä¿¡ ±â¿©ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á¿¡¼ °ü·ùÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Àü ¼¼°èÀûÀ¸·Î Àå±â ÀÌ½Ä ÇÁ·Î±×·¥ÀÌ È®´ëµÊ¿¡ µû¶ó °ü·ù ½Ã½ºÅÛ ½ÃÀåÀÇ Àü¸ÁÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Àüü °ü·ù ½Ã½ºÅÛ ½ÃÀåÀº ±â¼ú, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.
»ó¿Â ±â°è °ü·ù ºÐ¾ß´Â 2023³âºÎÅÍ 2032³â±îÁö Å« ¹ßÀüÀ» ÀÌ·ê °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ Ã·´Ü ±â¼úÀº ÀÌ½Ä ÁßÀÎ Àå±â¸¦ Á¤»ó ü¿Â¿¡ °¡±î¿î ¿Âµµ¿¡¼ º¸Á¸ÇÏ°í Æò°¡ÇÏ¿© Àå±âÀÇ »ýÁ¸À²°ú ±â´ÉÀ» Çâ»ó½Ãŵ´Ï´Ù. »ó¿Â ±â°èÀû °ü·ù´Â ´õ ³ªÀº Àå±â Æò°¡¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÌ½Ä ¼º°ø ½Ã°£À» ¿¬ÀåÇϱ⠶§¹®¿¡ ÀÌ½Ä ½Ã¼ú¿¡¼ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖÀ¸¸ç, °ü·ù ½Ã½ºÅÛ ½ÃÀå ¼öÀÍ¿¡ ´ëÇÑ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ ±â¿©¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
¼¼Æ÷ °ü·ù ½Ã½ºÅÛ ºÐ¾ß´Â 2023³âºÎÅÍ 2032³â±îÁö µÎµå·¯Áø CAGRÀ» ±â·ÏÇÒ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼ö Àåºñ´Â ¼¼Æ÷ ¹è¾ç ¹× Á¶Á÷ °øÇÐ ÀÀ¿ë ºÐ¾ß¿¡ ÇʼöÀûÀ̸ç, ¼¼Æ÷¿Í Á¶Á÷À» ¼ºÀå½Ã۱â À§ÇÑ ÅëÁ¦µÈ ȯ°æÀ» Á¦°øÇÕ´Ï´Ù. ¿¬±¸ÀÚ¿Í »ý¸í°øÇÐÀÚµéÀº ¼¼Æ÷ °ü·ù ½Ã½ºÅÛÀ» Ȱ¿ëÇÏ¿© »ý¸®Àû Á¶°ÇÀ» ÀçÇöÇϰí, ¼¼Æ÷ °Åµ¿À» ¿¬±¸Çϰí, ÷´Ü Ä¡·á¹ýÀ» °³¹ßÇÕ´Ï´Ù. Á¤¹ÐÇϰí È¿À²ÀûÀÎ ¼¼Æ÷ °ü·ù ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â °ü·ù ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» Áö¼ÓÀûÀ¸·Î °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ °ü·ù ½Ã½ºÅÛ »ê¾÷Àº 2023³âºÎÅÍ 2032³â±îÁö ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀÔ´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í Àå±â ÀÌ½Ä °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó °í±Þ °ü·ù ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ó¿Â ±â°è °ü·ù¿Í Çõ½Å ±â¼úÀÌ À¯·´ ÇコÄÉ¾î ºÐ¾ß¿¡¼ °¢±¤À» ¹ÞÀ¸¸ç ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. À¯·´Àº ÀÌ½Ä ¼º°ú Çâ»ó°ú Àå±â ºÎÁ·¿¡ ´ëÇÑ ´ëÀÀ¿¡ ÁßÁ¡À» µÎ°í ÀÖ¾î ÀÇ·á ºÐ¾ß¿¡¼ °ü·ù ½Ã½ºÅÛÀÇ ¸Å¿ì Áß¿äÇÑ ½ÃÀåÀÓ¿¡´Â º¯ÇÔÀÌ ¾ø½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå °ü·ù ½Ã½ºÅÛ ¾÷°è ÀλçÀÌÆ®
- »ýÅÂ°è ºÐ¼®
- ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
- ¼ºÀå ÃËÁø¿äÀÎ
- ½ÉÇ÷°üÁúȯ ¹× È£Èí±âÁúȯ À¯º´·ü Áõ°¡
- Àå±â ÀÌ½Ä °Ç¼ö Áõ°¡
- °í·ÉÈ »çȸÀÇ ´Ù¹ß¼º Àå±âºÎÀü ¹ß»ý·ü Áõ°¡
- ÷´Ü °ü·ù ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀÎ½Ä È®»ê
- ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
- °ü·ù ½Ã½ºÅÛÀÇ °íºñ¿ë
- ¼¼Æ÷ ±â¹Ý ¿¬±¸¿¡ °üÇÑ À±¸®Àû ¿ì·Á
- ¼ºÀå °¡´É¼º ºÐ¼®
- COVID-19 ¿µÇ⠺м®
- ±ÔÁ¦ »óȲ
- ÁÖ¿ä ½ÃÀå µ¿Çâ
- »óȯ ½Ã³ª¸®¿À
- ±â¼ú Àü¸Á
- ÇâÈÄ ½ÃÀå µ¿Çâ
- ¹ë·ùüÀÎ ºÐ¼®
- °ÝÂ÷ ºÐ¼®
- Porters ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå °æÀï »óȲ
- ¼·Ð
- ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
- ¼¼°è ±â¾÷ Á¡À¯À² ºÐ¼®
- º¥´õ ¸ÅÆ®¸¯½º ºÐ¼®
- °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
- Àü·« ´ë½Ãº¸µå
Á¦5Àå °ü·ù ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¹æ¹ýº°
- ÁÖ¿ä µ¿Çâ : ¹æ¹ýº°
- Àú¿Â ±â°è °ü·ù
- »ó¿Â ±â°è °ü·ù
Á¦6Àå °ü·ù ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°
- ÁÖ¿ä µ¿Çâ : ÄÄÆ÷³ÍÆ®º°
- »ê¼Ò °ø±Þ Àåºñ
- Àΰø½ÉÆó
- °ü·ù ÆßÇÁ
- ¸ð´ÏÅ͸µ ½Ã½ºÅÛ
- ¹ÙÀÌ¿À¸®¾×ÅÍ °ü·ù ½Ã½ºÅÛ
- ±âŸ
Á¦7Àå °ü·ù ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°
- ÁÖ¿ä µ¿Çâ : ¿ëµµº°
- Àΰø ½ÉÆó °ü·ù ½Ã½ºÅÛ
- ¼¼Æ÷ °ü·ù ½Ã½ºÅÛ
- »ýü¿Ü Àå±â °ü·ù ½Ã½ºÅÛ
Á¦8Àå °ü·ù ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°
- ÁÖ¿ä µ¿Çâ : ¿ëµµº°
- º´¿ø
- ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
- ±âŸ
Á¦9Àå °ü·ù ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°
- ÁÖ¿ä µ¿Çâ : Áö¿ªº°
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ½º¿þµ§
- Æú¶õµå
- ³×´ú¶õµå
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- È£ÁÖ
- Çѱ¹
- Àεµ³×½Ã¾Æ
- ű¹
- Çʸ®ÇÉ
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ¾Æ¸£ÇîÆ¼³ª
- ÄÝ·Òºñ¾Æ
- Ä¥·¹
- Æä·ç
- MEA
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- À̽º¶ó¿¤
- ÀÌÁýÆ®
- ÅÍŰ
Á¦10Àå ±â¾÷ °³¿ä
- ALA Scientific Instruments, Inc.
- Bioptechs Inc.
- Cytiva
- Getinge AB
- Harvard Bioscience, Inc.
- Lifeline Scientific, Inc.
- LivaNova
- Medtronic, plc
- Merck KGaA
- Nipro Corporation
- Repligen Corporation
- Spectrum Laboratories, Inc.
- Terumo Corporation
- XENIOS AG
ksm
¿µ¹® ¸ñÂ÷
Global Perfusion Systems Market will witness 4.6% CAGR between 2023 and 2032. The increasing prevalence of cardiovascular and respiratory diseases necessitates advanced perfusion systems for organ transplants and surgeries. Advancements in medical technology have led to more sophisticated and efficient perfusion systems. Rising FDA approvals for the latest technological devices involving or associated with profusions support market growth.
For instance, in August 2023, LivaNova PLC, a leading medical technology company, announced the attainment of regulatory clearances from the FDA and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM). Integrated into the Essenz™ Perfusion System, the monitor enables perfusionists to access and manage blood parameters conveniently from the system's cockpit, eliminating the need for extra monitors or holders. The rising aging population contributes to the demand for organ transplantation, further fueling market growth. Additionally, the growing awareness of the importance of perfusion in healthcare and the expansion of organ transplant programs globally drive the perfusion systems market outlook.
The overall Perfusion Systems Market is classified based on technique, application, and region.
The normothermic machine perfusion segment will undergo significant development from 2023 to 2032. This advanced technique preserves and evaluates organs at near-normal body temperatures during transplantation, enhancing their viability and functionality. Normothermic machine perfusion is becoming increasingly crucial in transplant procedures, as it allows for better organ assessment and extends the window of time for successful transplantation, driving the contribution of such systems in the perfusion systems market revenue.
The cell perfusion system segment will register a commendable CAGR from 2023 to 2032. These specialized devices are vital in cell culture and tissue engineering applications, providing a controlled environment for nurturing cells and tissues. Researchers and biotechnologists rely on cell perfusion systems to replicate physiological conditions, study cell behavior, and develop advanced therapies. The demand for precise and efficient cell perfusion technology continues to drive the perfusion systems market growth.
Europe Perfusion Systems Industry will showcase an appreciable CAGR from 2023 to 2032. The region's well-established healthcare infrastructure and a growing number of organ transplant procedures drive the need for advanced perfusion systems. Normothermic machine perfusion and innovative technologies are gaining prominence in European healthcare, further contributing to market growth. With a focus on improving transplant outcomes and addressing organ shortages, Europe remains a pivotal market for perfusion systems in the medical field.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Industry coverage
- 1.2 Market scope & definition
- 1.3 Base estimates & calculations
- 1.4 Forecast parameters
- 1.5 COVID-19 impact analysis at global level
- 1.6 Data validation
- 1.7 Data Sources
- 1.7.1 Primary
- 1.7.2 Secondary
- 1.7.2.1 Paid sources
- 1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Perfusion systems industry 360 degree synopsis, 2018 - 2032
- 2.2 Business trends
- 2.3 Regional trends
- 2.4 Technique trends
- 2.5 Component trends
- 2.6 Application trends
- 2.7 End-use trends
Chapter 3 Perfusion Systems Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of cardiovascular and respiratory diseases
- 3.2.1.2 Rising number of organ transplantations
- 3.2.1.3 Increasing incidence of multiple organ failure among ageing population
- 3.2.1.4 Rising awareness regarding advance perfusion systems
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of perfusion systems
- 3.2.2.2 Ethical Concerns related to cell - based research
- 3.3 Growth potential analysis
- 3.3.1 By technique
- 3.3.2 By component
- 3.3.3 By application
- 3.3.4 By end-use
- 3.4 COVID- 19 impact analysis
- 3.5 Regulatory landscape
- 3.6 Key market trends
- 3.7 Reimbursement scenario
- 3.8 Technology landscape
- 3.9 Future market trends
- 3.10 Value chain analysis
- 3.11 Gap Analysis
- 3.12 Porter's analysis
- 3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
- 4.1 Introduction
- 4.2 Company matrix analysis, 2022
- 4.3 Global company market share analysis, 2022
- 4.4 Vendor matrix analysis
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard, 2022
Chapter 5 Perfusion Systems Market Size and Forecast, By Technique (USD Million)
- 5.1 Key trends, by technique
- 5.2 Hypothermic machine perfusion
- 5.3 Normothermic machine perfusion
Chapter 6 Perfusion Systems Market Size and Forecast, By Component (USD Million)
- 6.1 Key trends, by component
- 6.2 Oxygenators
- 6.3 Heart-lung machine
- 6.4 Perfusion pumps
- 6.5 Monitoring system
- 6.6 Bioreactor perfusion system
- 6.7 Others
Chapter 7 Perfusion Systems Market Size and Forecast, By Application (USD Million)
- 7.1 Key trends, by application
- 7.2 Cardiopulmonary perfusion system
- 7.3 Cell perfusion system
- 7.4 Ex-vivo organ perfusion system
Chapter 8 Perfusion Systems Market Size and Forecast, By End-use (USD Million)
- 8.1 Key trends, by end-use
- 8.2 Hospitals
- 8.3 Ambulatory surgical centers
- 8.4 Others
Chapter 9 Perfusion Systems Market Size and Forecast, By Region (USD Million)
- 9.1 Key trends, by region
- 9.2 North America
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Sweden
- 9.3.7 Poland
- 9.3.8 The Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Thailand
- 9.4.8 Philippines
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Colombia
- 9.5.5 Chile
- 9.5.6 Peru
- 9.6 MEA
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Israel
- 9.6.5 Egypt
- 9.6.6 Turkey
Chapter 10 Company Profiles
- 10.1 ALA Scientific Instruments, Inc.
- 10.2 Bioptechs Inc.
- 10.3 Cytiva
- 10.4 Getinge AB
- 10.5 Harvard Bioscience, Inc.
- 10.6 Lifeline Scientific, Inc.
- 10.7 LivaNova
- 10.8 Medtronic, plc
- 10.9 Merck KGaA
- 10.10 Nipro Corporation
- 10.11 Repligen Corporation
- 10.12 Spectrum Laboratories, Inc.
- 10.13 Terumo Corporation
- 10.14 XENIOS AG
°ü·ÃÀÚ·á